The company's average rating is Hold from 2 analysts.
We provide trade advice to complement the prevailing
expert consensus on Adamis Pharmaceuticl. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
The company has Profit Margin (PM) of
(298.84) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of
(225.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.25.
Adamis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
Adamis Pharma
financial leverage refers to using borrowed capital as a funding source to finance Adamis Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Adamis Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Adamis Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Adamis Pharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Adamis Pharma's total debt and its cash.
Adamis Pharmaceuticl reported the previous year's revenue of 16.53
M. Net Loss for the year was (49.39
M) with profit before overhead, payroll, taxes, and interest of 1.63
M.
Deferred Revenue Breakdown
Adamis Pharmaceuticl Deferred Revenue yearly trend continues to be very stable with very little volatility. Deferred Revenue is likely to drop to about 841.2
K. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Adamis Pharmaceuticl Deferred Revenue is very stable at the moment as compared to the past year. Adamis Pharmaceuticl reported last year Deferred Revenue of 950,070
| 2010 | 54,478 |
| 2017 | 14,758 |
| 2018 | 1.01 Million |
| 2019 | 915,671 |
| 2020 | 950,070 |
| 2021 | 841,179 |
Adamis Pharmaceuticl implied volatility may change after the decline
Recent value at risk is at -6.12. Adamis Pharmaceuticl is displaying above-average volatility over the selected time horizon. Investors should scrutinize Adamis Pharmaceuticl independently to ensure intended market timing strategies are aligned with expectations about Adamis Pharmaceuticl volatility. Adamis Pharmaceuticl is a potential penny stock. Although Adamis Pharmaceuticl may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Adamis Pharmaceuticl. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Adamis instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
The Current Takeaway on Adamis Pharmaceuticl Investment
Although other entities under the drug manufacturers—specialty & generic industry are still a bit expensive, Adamis Pharmaceuticl may offer a potential longer-term growth to insiders. With a less-than optimistic outlook for your 90 days horizon, it may be a good time to exit some or all of your Adamis Pharmaceuticl holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Adamis Pharmaceuticl.
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Adamis Pharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com